Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Clinical trial NCT04712721 · TERMINATED

Trial details

NCT number: NCT04712721
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Glioblastoma Multiforme Brain Neoplasms Gastroesophageal Adenocarcinoma Pancreatic Ductal Adenocarcinoma

Start date: 2021-10-14
Primary completion: 2024-06-18
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.